Glycocalyx

GlycoCx is a biotechnology company focused on developing therapeutics that protect and restore the endothelial glycocalyx, a protective sugar-rich layer lining the interior of all blood vessels. Damage to this layer is a primary driver of vascular permeability and inflammation in critical illnesses such as sepsis and acute respiratory distress syndrome (ARDS). The company's lead programs utilize recombinant proteins and small molecules designed to inhibit the enzymes that degrade the glycocalyx or to replace its essential components. By stabilizing the vascular barrier, GlycoCx aims to prevent organ failure and improve outcomes for patients with life-threatening inflammatory conditions. The company is currently advancing its candidates through pre-clinical development.